SCHEMBL21458240

SCHEMBL21458240

COC(=O)c1ccc(Cl)c2ccn(Cc3ccc(C4CCC4)c(F)c3)c12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 1/20 0.36
FGFR4 P22455 1/20 0.36
OPRL1 P41146 1/20 0.35
PRPS1 P60891 1/20 0.35
ACHE P22303 1/20 0.35
TOP1 P11387 1/20 0.34
MAPT P10636 2/20 0.34
PANK3 Q9H999 2/20 0.34
POLB P06746 1/20 0.34
OPRK1 P41145 1/20 0.34
THRA P10827 2/20 0.33
THRB P10828 2/20 0.33
CFD P00746 1/20 0.33
FAAH O00519 1/20 0.33
CNR1 P21554 1/20 0.33
CNR2 P34972 1/20 0.33
P2RX7 Q99572 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30843253 1.00 FGFR1 (0.36) FGFR1FGFR4OPRL1PRPS1ACHE
SCHEMBL21458231 0.84 ALOX5AP (0.36) FGFR1FGFR4OPRL1MAPTPANK3
SCHEMBL30843285 0.84 ALOX5AP (0.36) FGFR1FGFR4OPRL1MAPTPANK3
SCHEMBL26602513 0.77 HSP90AA1 (0.42) MAPTP2RX7KDM4EALDH1A1KMT2A
SCHEMBL21458236 0.75 CA1 (0.43) MAPTKDM4EMEN1ALDH1A1RAB9A
SCHEMBL30843272 0.75 CA1 (0.43) MAPTKDM4EMEN1ALDH1A1RAB9A
SCHEMBL26602446 0.73 MAPK10 (0.38) FGFR1FGFR4MAPTPOLBKDM4E
SCHEMBL26601878 0.72 L3MBTL1 (0.46) MAPTPOLBTHRBCNR1CNR2
SCHEMBL21482082 0.72 KDM4E (0.39) MAPTPOLBCNR1CNR2KDM4E
SCHEMBL21458237 0.71 HSP90AA1 (0.39) FGFR1FGFR4POLBP2RX7KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250353829-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS INC (US) 2025-11-20 US disclosed
US-12215093-B2 Bicyclic carboxamides and methods of use thereof TEMPEST THERAPEUTICS, INC. (US) 2025-02-04 US disclosed
US-20240150316-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. 2024-05-09 US disclosed
CN-112313208-B Bicyclic carboxamides and methods of use thereof 泰普斯特医疗公司 2024-04-19 CN disclosed
US-11795156-B2 Bicyclic carboxamides and methods of use thereof TEMPEST THERAPEUTICS, INC. (US) 2023-10-24 US disclosed
US-20230045612-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. 2023-02-09 US disclosed
US-11472789-B2 Bicyclic carboxamides and methods of use thereof TEMPEST THERAPEUTICS, INC. (US) 2022-10-18 US disclosed
US-10968201-B2 Bicyclic carboxamides and methods of use thereof TEMPEST THERAPEUTICS, INC. (US) 2021-04-06 US disclosed
CN-112313208-A Bicyclic carboxamides and methods of use thereof 泰普斯特医疗公司 2021-02-02 CN disclosed
US-20210024491-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. 2021-01-28 US disclosed
US-20190315712-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. 2019-10-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11795156-B2 Bicyclic carboxamides and methods of use thereof PTGER4, PTGER2, CNR2 FGFR1 2816/4885FGFR4 1789/4885OPRL1 42/4885
US-10968201-B2 Bicyclic carboxamides and methods of use thereof PTGER4, PTGER2, CNR2 FGFR1 2816/4885FGFR4 1789/4885OPRL1 42/4885
US-20240150316-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 FGFR1 2816/4885FGFR4 1789/4885OPRL1 42/4885
US-11472789-B2 Bicyclic carboxamides and methods of use thereof PTGER4, PTGER2, CNR2 FGFR1 2816/4885FGFR4 1789/4885OPRL1 42/4885
US-20230045612-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 FGFR1 2816/4885FGFR4 1789/4885OPRL1 42/4885
US-20210024491-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 FGFR1 2816/4885FGFR4 1789/4885OPRL1 42/4885
US-20250353829-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 FGFR1 2816/4885FGFR4 1789/4885OPRL1 42/4885
US-12215093-B2 Bicyclic carboxamides and methods of use thereof PTGER4, PTGER2, CNR2 FGFR1 2816/4885FGFR4 1789/4885OPRL1 42/4885
US-20190315712-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 FGFR1 2816/4885FGFR4 1789/4885OPRL1 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.